Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents

References

• Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1–S4.
   PubMed Web of Science ®Google Scholar
• Institute for Safe Medications Practices. ISMP’s list of high-alert medications. Huntingdon Valley (PA): ISMP; 2007. [cited 2015 Jan 27]. Available from: http://www.ismp.org/tools/highalertmedications.pdf
   Google Scholar
• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(Suppl 2):32–44.
   PubMed Web of Science ®Google Scholar
• Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30:3012–3019.
   PubMed Web of Science ®Google Scholar
• Goodin S, Griffith N, Chen B, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7:7–12.
   PubMedGoogle Scholar
• Weingart SN, Spencer J, Buia S, et al. Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract. 2011;7:2–6.
   PubMedGoogle Scholar
• Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407–409.
   PubMed Web of Science ®Google Scholar
• Kav S, Johnson J, Rittenberg C, et al. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer. 2008;16:1075–1083.
   PubMed Web of Science ®Google Scholar
• Bayraktar-Ekincioglu A, Demirkan K, Keskin B, et al. Potential drug interactions and side effects in an outpatient oncology clinic: a retrospective descriptive study. Eur J Hosp Pharm. 2014;21:216–221.
   Google Scholar
• Neuss MN, Polovich M, McNiff K, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncol Nurs Forum. 2013;40:225–233.
   PubMed Web of Science ®Google Scholar
• Kav S, Schulmeister L, Nirenberg A, et al. Development of the MASCC Teaching Tool for patient receiving oral agents for cancer. Support Care Cancer. 2010;15:1075–1083.
   Google Scholar
• European medicines agency. Sciences medicines health. London: EMA drug information, summary of product characteristics; 2015. [cited 2015 Oct 5]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=wc0b01ac058001d12.
   Google Scholar
• Gebbia V, Bellavia G, Ferrau F, et al. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapy and biologic agents. Expert Opin Drug Saf. 2012;11(Suppl 1):S49–59.
   Google Scholar
• Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35:626–630.
   PubMed Web of Science ®Google Scholar
• Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract. 2014;10:255–268.
   PubMedGoogle Scholar
• Fleisher B, Unum J, Shao J, et al. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. J Pharm Sci. 2015;104:266–275.
   PubMed Web of Science ®Google Scholar
• Yin OQ, Gallagher N, Li A, et al. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2010;50:188–194.
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Carls A. Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol. 2014;10:359–377.
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao HT, Liu CX, et al. Drugs as CYP 3A4 probes, inducers and, inhibitors. Drug Metb Rev. 2007;39:699–721.
   PubMed Web of Science ®Google Scholar
• Bulsink A, Imholz AL, Brouwers JR, et al. Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm. 2013;35:101–107.
   PubMed Web of Science ®Google Scholar
• British Columbia Cancer Agency. Agency of the Provincial Health Services Authority. Vancouver (BC): Cancer Management guidelines [ Updated May 2011; cited 2014 Oct 5]. Available from: http://www.bccancer.bc.ca/default.htm.
   Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Bethesda (MD): U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2010. [cited 2014 Nov 4]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf
   Google Scholar
• Noens L, Van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–5411.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86:471–474.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behavior in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904–909.
   PubMed Web of Science ®Google Scholar
• Trivedi D, Landsman-Blumberg P, Darkow T, et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Pharm. 2014;20:1006–1015.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Cavanaugh JJ, Lindsey KN, Shilliday BB, et al. Pharmacist-coordinated multidisciplinary hospital follow-up visits improve patient outcomes. J Manag Care Spec Pharm. 2015;21:256–260.
   PubMed Web of Science ®Google Scholar
• EORTC Quality of Life Department. Belgium. EORTC QLQ-C30 version 3. [ cited 2014 Sep 28]. Available from: http://www. eortc.be/home/qol/downloads/f/C30/QLQ-C30%20Spanish- Mexican.pdf
   Google Scholar
• Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep. 2010;12:247–252.
   PubMed Web of Science ®Google Scholar
• Wong SF, Bounthavong M, Nguyen C, et al. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–965.
   PubMedGoogle Scholar
• Rittenberg CN. Meeting educational needs and enhancing adherence of patients receiving oral agents through use of the MASCC Oral Agent Teaching Tool. Eur Oncol Haematol. 2012;8:97–100.
   Google Scholar
• Li E, Schleif R, Edelen B. Hospital management of outpatient oncology treatment decisions: a survey to identify strategies and concerns. J Oncol Pract. 2013;9:248–254.
   Google Scholar
• Puts MT, Costa Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drug Aging. 2009;26:519–536.
   PubMed Web of Science ®Google Scholar
• Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–1257.
   PubMed Web of Science ®Google Scholar
• Lexi-comp ONLINE. Hudson (OH): Lexi-Comp; 1978–2015. [cited 2014 Nov 28] Available from: http://online.lexi.com/lco/action/home/.
   Google Scholar
• Carcelero E, Anglada H, Tuset M, et al. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf. 2013;12:403–420.
   PubMed Web of Science ®Google Scholar
• Narasimhan NI, Dorer DJ, Niland K, et al Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther. 2013;38:440–444.
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323–329.
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, De Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349–358.
   PubMed Web of Science ®Google Scholar
• Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid Leukemia: the role of the midlevel practitioner. J Support Oncol. 2012;10:14–24.
   PubMedGoogle Scholar
• Williams LA, García-Gonzalez AG, Ault P, et al. Symptom burden in chronic myeloid leukemia (CML). Blood. 2013;122:614–617.
   Web of Science ®Google Scholar
• Jabbour EJ, Kantarjian H, Eliasson L, et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukaemia. Am J Hematol. 2012;87:687–691.
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CC, Mangnus D, et al. The use of erlotinib in daily practice: a study on adherence and patients’ experiences. BMC Cancer. 2011;11:284.
   PubMed Web of Science ®Google Scholar
• Coquan E, Henri P, De Raucourt S, et al. Management of adverse effects of targeted therapy toxicities in oncology. Rev Prat. 2012;62(1):17–25.
   PubMedGoogle Scholar
• Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015;75:1335–1348.
   PubMed Web of Science ®Google Scholar
• Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care. 2014;23:22–35.
   PubMed Web of Science ®Google Scholar
• Abraham I, Noens L, De Bock R, et al. The variance in patient reported non adherence with imatinib treatment in chronic myeloid leukemia is attributable to both physicians and patients – results from the ADAGIO study. Haematologica. 2008;93:S1.
   Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61–69.
   PubMed Web of Science ®Google Scholar
• Halpern R, Barghout V, Mody-Patel D, et al. Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate. J Clin Oncol. 2008;26:20.
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–496.
   PubMed Web of Science ®Google Scholar